Xenon Submits Azetukalner NDA to FDA for Focal Seizures, Pauses Psychiatry Enrollment

RegulationProduct / Tech Impact 4
โดย GlobeNewswire·US·Read original
Summary · why it matters

Xenon Pharmaceuticals has submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner in focal seizures, based on positive data from the Phase 2b X-TOLE and Phase 3 X-TOLE2 trials in which all four doses produced statistically significant reductions in monthly seizure frequency versus placebo. The company also said it has voluntarily paused enrollment of new patients in its ongoing psychiatry studies in major depressive disorder and bipolar depression after an analysis of neuropsychiatric adverse events, though patients already enrolled remain on study and the pause is expected to be temporary. Enrollment in the X-NOVA2 study in MDD has reached approximately 80% of its initial target of 450 patients, and topline data are now expected in the first quarter of 2027. The Phase 3 X-TOLE3 and X-ACKT epilepsy studies continue to enroll focal seizure and primary generalized tonic-clonic seizure patients, respectively, and the epilepsy program has generated more than 1,500 patient-years of safety and exposure data. Xenon will host a conference call today at 4:30 pm Eastern Time to discuss the NDA submission and the psychiatry program update.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Xenon Pharmaceuticals Inc
XENE
± MixedRegulationTechnologyrelevance

Xenon submitted an NDA to the FDA for azetukalner in focal seizures based on positive Phase 2b/Phase 3 data, a regulatory milestone.

Theme Impact 1

Related news

Axsome Therapeutics Reports New Clinical Data in Depression and Alzheimer's Agitation

Axsome Therapeutics reported new clinical data in major depressive disorder and Alzheimer's disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome's central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms, and management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. The company is advancing multiple late-stage clinical programs, including AXS-05, AXS-12, AXS-14, and several solriamfetol indications, and the fresh congress results give more clinical detail around AXS-05 in depression and Alzheimer's agitation, feeding the thesis that future CNS indications can broaden the revenue mix beyond Auvelity, Sunosi and SYMBRAVO. Axsome, a mid-sized US pharmaceuticals player with a market cap of $11.2b, competes alongside larger CNS-focused drug developers such as Biogen and Eli Lilly and smaller specialists. The same update also stress tests a key risk: management must commercialise several CNS assets at once while running high R&D and SG&A spending, with payer scrutiny and strong rivals in both categories.
AXSM ▲
Biotech & Genomic Medicine
Simply Wall St·3hRead more →
▲2

Novartis Acquires Full Rights to Sironax Brain Delivery Platform

Novartis agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier, expanding its toolkit for research into central nervous system disorders where treatment options remain limited. Novartis is a large pharmaceuticals group with a CHF218.8 billion market cap that researches, develops, manufactures, distributes, markets, and sells medicines globally, so gaining access to differentiated delivery technology directly links into its existing focus on complex neurological treatments. The Sironax platform speaks to the same advanced-therapy thesis that underpins Cosentyx's CHMP progress and remibrutinib's Phase 3 data, as Novartis seeks to own hard-to-reach biology where rivals like Roche and Biogen also compete for neurologists' attention. The flip side is that every new modality adds complexity, and recent trial setbacks such as pelacarsen and del-desiran keep development risk front and center, with analysts flagging that stacking capital-intensive projects on top of share buybacks could stretch the balance sheet of a business already carrying a high level of debt.
NOVN.SW ▲
Biotech & Genomic Medicine ▲
Simply Wall St·4hRead more →
2

AbbVie Unveils New VRAYLAR Real-World and Pediatric Safety Data at Psych Congress 2026

AbbVie shared new real-world and pediatric safety data for VRAYLAR in major depressive disorder and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups, while the pediatric data added information on safety and use in younger patients with mood disorders. AbbVie, a research-focused biopharmaceutical group with a US$466.6b market cap, positions VRAYLAR within a broad portfolio targeting chronic conditions including complex psychiatric disorders. The company said the next concrete checkpoint will be how these data feed into prescribing and label use over the next year, particularly uptake of newly approved low dose VRAYLAR in pediatric and adjunctive MDD settings, trackable in reported prescription trends and segment sales through 2027.
ABBV ▲
Biotech & Genomic Medicine
Simply Wall St·4hRead more →
© 2026 MarketDXNews